Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

Overview of attention for article published in Drug Design, Development and Therapy, November 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

policy: 1 policy source

twitter: 10 X users

Citations

dimensions_citation: 48 Dimensions

Readers on

mendeley: 38 Mendeley

Summary Policy documents X Dimensions citations

So far, Dimensions has found 48 publications that cite this research output.

48

The most recent citing publications are shown below. View all 48 publications that cite this research output on Dimensions.

Expression and characterization of recombinant IL-1Ra in Aspergillus oryzae as a system

Article in BMC Biotechnology (June 2023)

High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center

Article in Inflammopharmacology (January 2023)

High Dose Intravenous Anakinra Treatment is Safe and Effective in Severe and Critical COVID-19 Patients: A Propensity Score Matched Study in a Single Center

Preprint in Research Square (January 2023)